Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
NCT03535363 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6
Last updated 2024-03-13
Summary
Investigating potential of controlling brain metastases in patients with EGFR positive NSCLC.
Conditions
Interventions
- DRUG
-
Drug: Osimertinib 80mg or 40mg
Sponsors & Collaborators
-
Case Comprehensive Cancer Center
lead OTHER
Principal Investigators
-
Glen Stevens, DO, PhD · Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-10-26
- Primary Completion
- 2022-04-01
- Completion
- 2022-04-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
NCT06376084 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
NCT03567642 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
NCT05104281 ·Status: UNKNOWN ·Phase: PHASE3
-
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
NCT06039683 ·Status: COMPLETED
-
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
NCT03122717 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
NCT05513664 ·Status: UNKNOWN
-
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
NCT06970639 ·Status: RECRUITING ·Phase: PHASE3
-
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
NCT04410796 ·Status: RECRUITING ·Phase: PHASE2
-
A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
NCT03239340 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)
NCT05998993 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
NCT06319950 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
NCT06538038 ·Status: RECRUITING
-
Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations
NCT04695925 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
NCT05009836 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Osimertinib for NSCLC With Uncommon EGFR Mutations
NCT05421936 ·Status: SUSPENDED
-
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097 ·Status: RECRUITING ·Phase: PHASE3
-
Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis
NCT07239102 ·Status: COMPLETED
-
Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI
NCT04829019 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT04743505 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
NCT03392246 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer
NCT03460275 ·Status: UNKNOWN ·Phase: PHASE2
-
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NCT04870190 ·Status: UNKNOWN ·Phase: PHASE3
-
Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
NCT03891615 ·Status: UNKNOWN ·Phase: PHASE1
-
Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
NCT06613633 ·Status: COMPLETED
-
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer
NCT04974879 ·Status: UNKNOWN ·Phase: PHASE2